The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory

BioFactors

Volumn 41, Issue 3, 2015, Pages 153-159

  Namiri Kalantari, Ryan ^a   Gao, Feng ^a   Chattopadhyay, Arnab ^a   Wheeler, Aerin Alese ^a   Navab, Kaveh D ^a   Farias Eisner, Robin ^a   Reddy, Srinivasa T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammatory HDL; Apo A I mimetic peptides; Apolipoprotein A I (apo A I); Coronary heart disease (CHD); HDL; HDL inflammatory index (HII); LDL; Pro inflammatory HDL

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ANTIINFLAMMATORY AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PEPTIDE; PEPTIDOMIMETIC AGENT;

ACUTE PHASE RESPONSE; ATHEROSCLEROSIS; BIOMIMETICS; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENE EXPRESSION; HUMAN; LIPID OXIDATION; MOUSE MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; ANIMAL; CORONARY DISEASE; DIABETES MELLITUS; INFLAMMATION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; RISK FACTOR; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DIABETES MELLITUS; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; PEPTIDES; PEPTIDOMIMETICS; RISK FACTORS;

EID: 84931957602     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1205     Document Type: Review

References (52)

1. Ansell, B. J., Navab, M., Hama, S., Kamranpour, N., Fonarow, G., et al. (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation108, 2751-2756.
2. Kallio, R. (2000) Traditional and New Markers of Infection in Adult Cancer Patients in Adult Cancer Patients and the Possible Interfering Effect of Underlying Malignancy on These Markers. Doctoral Dissertation. Oulu, Finland: Oulu University Hospital, Department of Infection Control.
3. Cray, C., Zaias, J., and Altman, N. (2009) Acute phase response in animals: A review. Comp. Med. 59, 517-526.
4. Van Lenten, B. J., Hama, S. Y., de Beer, F. C., Stafforini, D. M., McIntyre, T. M., et al. (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96, 2758-2767.
5. Navab, M., Ananthramaiah, G. M., Reddy, S. T., Van Lenten, B. J., Ansell, B. J., et al. (2005) The double jeopardy of HDL. Ann. Med. 37, 173-178.
6. Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., and Dawber, T. R. (1977) High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am. J. Med. 62, 707-714.
7. Briel, M., Ferreira-Gonzalez, I., You, J. J., Karanicolas, P., Akl, E. A., et al. (2009) Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis. BMJ 338, b92.
8. Alexander, E. T., Tanaka, M., Kono, M., Saito, H., Rader, D. J., et al. (2009) Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I. J. Lipid Res. 50, 1409-1419.
9. Dodani, S., Kaur, R., Reddy, S., Reed, G. L., Navab, M., et al. (2008) Can dysfunctional HDL explain high coronary artery disease risk in South Asians? Int. J. Cardiol. 129, 125-132.
10. Roberts, C. K., Ng, C., Hama, S., Eliseo, A. J., and Barnard, R. J. (2006) Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J. Appl. Physiol. 101, 1727-1732.
11. Persegol, L., Verges, B., Gambert, P., and Duvillard, L. (2007) Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J. Lipid Res. 48, 1396-1401.
12. Perségol, L., Foissac, M., Lagrost, L., Athias, A., Gambert, P., et al. (2007) HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 50, 2384-2387.
13. Perségol, L., Vergès, B., Foissac, M., Gambert, P., and Duvillard, L. (2006) Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation. Diabetologia 49, 1380-1386.
14. Hedrick, C. C., Thorpe, S. R., Fu, M. X., Harper, C. M., Yoo, J., et al. (2000) Glycation impairs high-density lipoprotein function. Diabetologia 43, 312-320.
15. Kalantar-Zadeh, K., Kopple, J. D., Kamranpour, N., Fogelman, A. M., and Navab, M. (2007) HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 72, 1149-1156.
16. Rong, J. X., Li, J., Reis, E. D., Choudhury, R. P., Dansky, H. M., et al. (2001) Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104, 2447-2452.
17. Li, R., Chao, H., Ko, K. W., Cormier, S., Dieker, C., et al. (2011) Gene therapy targeting LDL cholesterol but not HDL cholesterol induces regression of advanced atherosclerosis in a mouse model of familial hypercholesterolemia. J. Genet. Syndr. Gene Ther. 2, 106.
18. Van Craeyveld, E., Gordts, S. C., Nefyodova, E., Jacobs, F., and De Geest, B. (2011) Regression and stabilization of advanced murine atherosclerotic lesions: A comparison of LDL lowering and HDL raising gene transfer strategies. J. Mol. Med. (Berl). 89, 555-567.
19. Badimon, J. J., Badimon, L., and Fuster, V. (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85, 1234-1241.
20. Plump, A. S., Scott, C. J., and Breslow, J. L. (1994) Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA 91, 9607-9611.
21. Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290, 2292-2300.
22. Patel, S., Drew, B. G., Nakhla, S., Duffy, S. J., Murphy, A. J., et al. (2009) Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J. Am. Coll. Cardiol. 53, 962-971.
23. Kaiser, E. T. and Kézdy, F. J. (1983) Secondary structures of proteins and peptides in amphiphilic environments (A Review). Proc. Natl. Acad. Sci. USA 80, 1137-1143.
24. Anantharamaiah, G. M., Jones, J. L., Brouillette, C. G., Schmidt, C. F., Chung, B. H., et al. (1985) Studies of synthetic peptide analogs of amphipathic helix: Structure of complexes with dimyristoyl phosphatidyl-choline. J. Biol. Chem. 260, 10248-10255.
25. Venkatachalapathi, Y. V., Phillips, M. C., Epand, R. M., Epand, R. F., et al. (1993) Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins 15, 349-359.
26. Yancey, P. G., Bielicki, J. K., Johnson, W. J., Lund-Katz, S., Palgunachari, M. N., et al. (1995) Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 34, 7955-7965.
27. Datta, G., Chaddha, M., Hama, S., Navab, M., Fogelman, A. M., et al. (2001) Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42, 1096-1104.
28. Garber, D. W., Datta, G., Chaddha, M., Palgunachari, M. N., Hama, S. Y., et al. (2001) A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42, 545-552.
29. Navab, M., Anantharamaiah, G. M., Hama, S., Garber, D. W., Chaddha, M., et al. (2002) Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation105, 290-292.
30. Van Lenten, B. J., Wagner, A. C., Anantharamaiah, G. M., Garber, D. W., Fishbein, M. C., et al. (2002) Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106, 1127-1132.
31. Ou, J., Ou, Z., Jones, D. W., Holzhauer, S., Hatoum, O. A., et al. (2003) L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107, 2337-2341.
32. Ou, J., Wang, J., Xu, H., Ou, Z., Sorci-Thomas, M. G., et al. (2005) Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ. Res. 97, 1190-1197.
33. Weihrauch, D., Xu, H., Shi, Y., Wang, J., Brien, J., et al. (2007) Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ. Physiol. 293, H1432-H1441.
34. Kruger, A. L., Peterson, S., Turkseven, S., Kaminski, P. M., Zhang, F. F., et al. (2005) D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111, 3126-3134.
35. Peterson, S. J., Husney, D., Kruger, A. L., Olszanecki, R., Ricci, F., et al. (2007) Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J. Pharmacol. Exp. Ther. 322, 514-520.
36. Peterson, S. J., Drummond, G., Kim, D. H., Li, M., Kruger, A. L., et al. (2008) L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J. Lipid Res. 49, 1658-1669.
37. Peterson, S. J., Kim, D. H., Li, M., Positano, V., Vanella, L., et al. (2009) The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J. Lipid Res. 50, 1293-1304.
38. DeLeve, L. D., Wang, X., Kanel, G. C., Atkinson, R. D., and McCuskey, R. S. (2008) Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am. J. Pathol. 173, 993-1001.
39. Buga, G. M., Frank, J. S., Mottino, G. A., Hendizadeh, M., Hakhamian, A., et al. (2006) D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J. Lipid Res. 47, 2148-2160.
40. Charles-Schoeman, C., Banquerigo, M. L., Hama, S., Navab, M., Park, G. S., et al. (2008) Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis. Clin. Immunol. 127, 234-244.
41. Buga, G. M., Frank, J. S., Mottino, G. A., Hakhamian, A., Narasimha, A., et al. (2008) D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet. J. Lipid Res. 49, 192-205.
42. Li, X., Chyu, K. Y., Faria Neto, J. R., Yano, J., Nathwani, N., et al. (2004) Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis inapolipoprotein E-null mice. Circulation 110, 1701-1705.
43. Handattu, S. P., Garber, D. W., Monroe, C. E., van Groen, T., Kadish, I., et al. (2009) Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 34, 525-534.
44. Navab, M., Anantharamaiah, G. M., Hama, S., Hough, G., Reddy, S. T., et al. (2005) D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 25, 1426-1432.
45. Van Lenten, B. J., Wagner, A. C., Jung, C. L., Ruchala, P., Waring, A. J., et al. (2008) Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49, 2302-2311.
46. Van Lenten, B. J., Wagner, A. C., Anantharamaiah, G. M., Navab, M., Reddy, S. T., et al. (2009) Apolipoprotein A-I mimetic peptides. Curr. Atheroscler. Rep. 11, 52-57.
47. Navab, M., Hama, S. Y., Anantharamaiah, G. M., Hassan, K., Hough, G. P., et al. (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J. Lipid Res. 41, 1495-1508.
48. Datta, G., Chaddha, M., Hama, S., Navab, M., Fogelman, A. M., et al. (2001) Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42, 1096-1104.
49. Navab, M., Anantharamaiah, G. M., Reddy, S. T., Hama, S., Hough, G., et al. (2005) Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 25, 1325-1331.
50. Navab, M., Anantharamaiah, G. M., Reddy, S. T., Van Lenten, B. J., and Fogelman, A. M. (2009) HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 58, 2711-2717.
51. Navab, M., Reddy, S. T., Van Lenten, B. J., and Fogelman, A. M. (2011) HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8, 222-232.
52. Anantharamaiah, G. M., Mishra, V. K., Garber, D. W., Datta, G., Handattu, S. P., et al. (2007) Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48, 1915-1923.